Efficacy and Safety of Meibomian Gland Dysfunction and Dry Eye With an LED Blue Treatment Device

Exclusion Criteria

• •1. Have a known hypersensitivity or contraindication to the investigational product or components.
• •2. Pregnancy or lactation
• •3. Subjects can be on the following medications if they have been on a stable dose for 12 weeks: topical cyclosporine, topical liftigrast and/or topical loteprednol etabonate. Tetracycline compounds, omega 3s, anticholinergics, anticonvulsants, antidepressants, retinoids, systemic immunosuppressive agents including oral corticosteroids, non-steroidals, antihistamines, or mast cell stabilizers, punctal plugs, contact lens wear and glaucoma medications.
• •4. Subjects must be unwilling to abstain from eyelash growth medications for the duration of the trial.
• •5. Subjects must not have had penetrating intraocular surgery, refractive surgery or corneal transplantation, eyelid surgery within 12 weeks prior to Visit 1.
• •6. Febrile illness within one week.
• •7. Treatment with another investigational drug or other intervention within one month.
• •8. Subjects with a history of herpetic keratitis.
• •9. Have serious or severe disease or uncontrolled medical condition that in the judgement of the investigator could confound study assessments or limit compliance.
• •10. Neuro-paralysis or pre-cancerous lesions in the area to be treated.
• •11. Radiation to the head or neck within past 12 months.
• •12. Planned radiation therapy or chemotherapy.
• •13. Anticipated relocation or extensive travel outside of the local study area preventing compliance with study procedures.
• •14. Legally blind in either eye.
• •15. Facial IPL treatment within 3 months of treatment.
• •16. Expression of Meibomian glands within 3 months prior to treatment.
• •\-